Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis
This study aims to evaluate the effects of ocrelizumab (OCZ) on familial Mediterranean fever (FMF) attacks in multiple sclerosis (MS) patients with FMF (MS+FMF patients). This retrospective observational study included 11 patients (2 males, 9 females; mean age 46.6±9.2; range, 22 to 55 years) with M...
Saved in:
Published in | Archives of rheumatology Vol. 36; no. 2; pp. 219 - 226 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Turkey
Turkish League Against Rheumatism
01.06.2021
Prof Sebnem Ataman, President Turkish League Against Rheumatism |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This study aims to evaluate the effects of ocrelizumab (OCZ) on familial Mediterranean fever (FMF) attacks in multiple sclerosis (MS) patients with FMF (MS+FMF patients).
This retrospective observational study included 11 patients (2 males, 9 females; mean age 46.6±9.2; range, 22 to 55 years) with MS+FMF hospitalized between January 2016 and July 2019. Demographic, clinical, and laboratory parameters and patient reported outcomes were analyzed in patients treated with OCZ for 18 months.
Combining OCZ with colchicine in MS+FMF patients significantly reduced the frequency of FMF attacks (p=0.003) and the frequency of joint attacks (p=0.002). Consistent with the clinical improvement, the maximum serum C-reactive protein levels were significantly decreased after combination therapy compared to before combination therapy (p=0.003). MS+FMF patients reported that FMF disease activity improved after OCZ therapy (Visual Analog Scale [VAS] 74±9.6 vs. VAS 46.5±8.1 mm, p=0.003).
Ocrelizumab therapy led to a prominent decrease in the frequency of FMF attacks, alleviated functional impairment, and improved quality of life in MS+FMF patients. |
---|---|
ISSN: | 2148-5046 1309-0291 2618-6500 1309-0283 |
DOI: | 10.46497/ArchRheumatol.2021.8229 |